Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: A pooled analysis

Thrombosis Research

Volumn 130, Issue 5, 2012, Pages 818-820

  Eriksson, Bengt I ^a   Dahl, Ola E ^b,c   Feuring, Martin ^d   Clemens, Andreas ^d   Noack, Herbert ^d   Hantel, Stefan ^d   Friedman, Richard J ^e   Huo, Michael ^f  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c INNLANDET HOSPITAL TRUST   (Norway)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Roper and Charleston Orthopedic Associates   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Body mass index; Dabigatran; Overweight; Total hip replacement; Total knee replacement; Venous thromboembolism

Indexed keywords

DABIGATRAN; ENOXAPARIN;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; BODY MASS INDEX; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84867577674     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.07.004     Document Type: Article

References (11)

1. S. Eichinger, G. Hron, C. Bialonczyk, M. Hirschl, E. Minar, and O. Wagner Overweight, obesity, and the risk of recurrent venous thromboembolism Arch Intern Med 168 2008 1678 1683
2. M.M. Samama An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study Arch Intern Med 160 2000 3415 3420
3. P.D. Stein, A. Beemath, and R.E. Olson Obesity as a risk factor in venous thromboembolism Am J Med 118 2005 978 980
4. A.W. Tsai, M. Cushman, W.D. Rosamond, S.R. Heckbert, J.F. Polak, and A.R. Folsom Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology Arch Intern Med 162 2002 1182 1189
5. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
6. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
7. B.I. Eriksson, O.E. Dahl, M.H. Huo, A.A. Kurth, S. Hantel, and K. Hermansson Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
8. K.H. Borch, S.K. Braekkan, E.B. Mathiesen, I. Njolstad, T. Wilsgaard, and J. Stormer Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study Arterioscler Thromb Vasc Biol 30 2010 121 127
9. K.A. Darvall, R.C. Sam, S.H. Silverman, A.W. Bradbury, and D.J. Adam Obesity and thrombosis Eur J Vasc Endovasc Surg 33 2007 223 233
10. J. Stangier, B.I. Eriksson, O.E. Dahl, L. Ahnfelt, G. Nehmiz, and H. Stahle Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement J Clin Pharmacol 45 2005 555 563
11. J. Stangier, and A. Clemens Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor Clin Appl Thromb Hemost 15 Suppl. 1 2009 9S 16S